Cite
MLA Citation
Manish Sharma et al.. “401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors.” Journal for immunotherapy of cancer, vol. 8, n.d., p. A426. http://access.bl.uk/ark:/81055/vdc_100144728985.0x000009